Tyrosine Kinase Inhibitor

Ascentage Pharma (NASDAQ: AAPG) reported four‑year Phase II data for olverembatinib in TKI‑resistant/intolerant chronic‑phase CML. Median event‑free survival was 21.2 months versus 2.9 months for best available therapy (P = 0.0159). Responses favored olverembatinib (85% CHR, 38% CCyR, 30% MMR). Safety was acceptable, with 7% vascular‑occlusion events and some grade ≥3 hematologic toxicities. The drug is approved in China and covered by the national reimbursement list; global rights depend on a Takeda option, and three Phase III registrational studies are underway.